Skip to content
MarketHOT
中文
← Latest news

Onconetix, Inc. (0001782107) (Filer)

SEC · EDGAR 财务披露 · November 9, 2026 at 8:00 AM ET

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 4, 2026

Onconetix, Inc.
(Exact name of registrant as specified in its charter)
Delaware   001-41294   83-2262816

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

201 E. Fifth Street, Suite 1900

Cincinnati, Ohio

  45202
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (513) 620-4101

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.00001 per share   ONCO   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

As previously disclosed in a Current Report on Form 8-K filed on October 26, 2026, on October 22, 2026, the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”) approved a one-for-ten (1:10) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock, par value $0.00001 per share (the “Common Stock”), pursuant to the authority granted by the Company’s stockholders at a special meeting held on April 30, 2026.

On November 4, 2026, the Company filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation, as amended (the “Charter”), with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Amendment became effective at 12:01 a.m. Eastern Time on November 6, 2026 (the “Effective Time”).

Pursuant to the Amendment, at the Effective Time, every ten (10) shares of the Company’s issued and outstanding Common Stock were automatically combined into one (1) issued and outstanding share of Common Stock, without any corresponding reduction in the number of authorized shares of Common Stock or any change in the par value per share. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would have been entitled to receive a fractional share will instead receive a cash payment (without interest) equal to such fraction multiplied by the closing sale price per share of the Common Stock on The Nasdaq Capital Market at the close of business on the trading day immediately preceding the Effective Time, as adjusted to give effect to the Reverse Stock Split.

As a result of the Reverse Stock Split, the number of outstanding shares of Common Stock was reduced from approximately 6.7 million shares to approximately 670,000 shares. Proportional adjustments were made to the number of shares of Common Stock issuable upon exercise or conversion of the Company’s outstanding equity awards, convertible preferred stock and warrants, as applicable, as well as the applicable exercise or conversion prices, in accordance with the terms of such securities.

The Common Stock began trading on a split-adjusted basis on The Nasdaq Capital Market on November 6, 2026, under the Company’s existing trading symbol “ONCO” and a new CUSIP number, 68237Q500

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed or furnished, as applicable, with this Current Report on Form 8-K:

Exhibit No.   Description
3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).
1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Onconetix, Inc.
   
November 9, 2026 By: /s/ David A. White
  Name: David A. White
  Title: Chief Executive Officer
2

View source ↗ · 中文页面